• 1
    Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.
  • 2
    Konoplev S, Hsieh PP, Chang CC, Medeiros LJ, Lin P. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis. Hum Pathol 2007; 38: 1760-1763.
  • 3
    Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985; 65: 803-809.
  • 4
    Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
  • 5
    Berer A, Jager E, Sagaster V, Streubel B, Wimazal F, Sperr WR, et al. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. Ann Hematol 2003; 82: 271-277.
  • 6
    Massberg S, von Andrian UH. Novel trafficking routes for hematopoietic stem and progenitor cells. Ann N Y Acad Sci 2009; 1176: 87-93.